Premium
Fluorescent imaging in a glioma model in vivo
Author(s) -
Nikas Dimitrios C.,
Foley James W.,
Black Peter M.
Publication year - 2001
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.1079
Subject(s) - fluorescence , glioma , in vivo , laser , fluorescence microscope , pathology , biomedical engineering , evans blue , chemistry , nuclear medicine , fluorescence lifetime imaging microscopy , brain tumor , preclinical imaging , optics , materials science , medicine , cancer research , biology , physics , microbiology and biotechnology
Background and Objective Nile blue dyes have been shown to have affinity for tumor tissue as compared to surrounding normal tissue and to be relatively non‐toxic. We have employed EtNBA, a lipophilic, fluorescent benzophenoxazine dye, in a murine model to image subcutaneous and intracranial U‐87 glioma implants. Study Design/Materials and Methods The imaging system used to detect fluorescence consists of a SIT video camera fitted with a zoom microscope‐magnifying lens. The tumor was illuminated with a 632.8‐nm diffuse beam from a helium–neon laser. The video image was processed using a Sony image processor to give real‐time pseudocolor and enhanced black and white images. Results Following subcutaneous injection of the dye at doses of 2.5–5.0 mg/kg bw, we observed a gradual increase of the fluorescent signal from the tumor which peaked 1–3 hours post‐injection with variable selectivity (typically 4:1) for tumor to normal surrounding tissues permitting the clear demarcation of the tumor. Conclusions The present in vivo study demonstrates that EtNBA is a safe and effective photodiagnostic agent, able to demarcate U87‐MG solid tumors in mice on a real‐time basis at a concentration of 2.5–5.0 mg/kg 1–3 hours after administration. Lasers Surg. Med. 29:11–17, 2001. © 2001 Wiley‐Liss, Inc.